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Introduction {#sec001}
============

Ginseng (*Panax ginseng* C. A. Meyer) belongs to the *Panax* genus of the *Araliaceae* family and has been used as a traditional medicine in Korea, China, and Japan for thousands of years \[[@pone.0191018.ref001]\]. Ginsenosides are the main active constituent found in ginseng and possess anti-cancer, anti-fatigue, anti-inflammatory, anti-oxidative, anti-viral, morphine-dependence attenuating, neuroprotective, and vasorelaxative properties \[[@pone.0191018.ref002]--[@pone.0191018.ref007]\]. Ginsenosides are divided into the protopanaxadiol (PPD) and protopanaxatriol (PPT) types, comprising of sugars linked to the dammarane (tetracyclic triterpene) skeleton. PPD-type ginsenosides contain no sugar, one, or two β-[d]{.smallcaps}-glucopyranoses linked to C-3; and no sugar, inner β-[d]{.smallcaps}-glucopyranose, or outer α-[l]{.smallcaps}-arabinopyranose, α-[l]{.smallcaps}-arabinofuranose, or β-[d]{.smallcaps}-xylopyranose linked to C-20 \[[@pone.0191018.ref008]\]. PPT-type ginsenosides contain no sugar, inner β-[d]{.smallcaps}-glucopyranose, or outer β-[d]{.smallcaps}-glucopyranose, β-[d]{.smallcaps}-xylopyranose, or β-[d]{.smallcaps}-rhamnopyranose linked to C-6; and no sugar or β-[d]{.smallcaps}-glucopyranose linked to C-20. Ginsenosides (Rb~1~, Rb~2~, Rc, Rd, Rg~1~, and Re) in wild ginseng was glycosylated forms contains more than 80%, however, deglycosylated forms in ginseng are present at low concentrations or do not exist. Deglycosylated forms shows greater biological and pharmaceutical activities than glycosylated forms owing to the higher bioavailability and better absorption in the gastrointestinal tract \[[@pone.0191018.ref009]\].

Compound K (C-K, 20-*O*-β-[d]{.smallcaps}-glucopyranosyl-20(*S*)-protopanaxadiol) is one molecule of β-[d]{.smallcaps}-glucopyranose linked to C-20 in the dammarane skeleton and can be produced from the hydrolysis of glycosylated PPD-type ginsenosides such as Rb~1~, Rb~2~, and Rc. C-K has demonstrated beneficial pharmaceutical properties such as anti-allergic, anti-arthritic, anti-carcinogenic, anti-diabetic and anti-inflammatory activities \[[@pone.0191018.ref006], [@pone.0191018.ref010]--[@pone.0191018.ref016]\]. C-K has also exhibited beneficial cosmetic properties such as the alleviation of skin wrinkles and xerosis \[[@pone.0191018.ref017]\]; and the prevention of UV-induced skin photo-aging and burn-wound healing \[[@pone.0191018.ref018]--[@pone.0191018.ref020]\]. Therefore, C-K has been used as an essential ingredient in cosmetics and traditional medicine. Diverse methods, such as heating, acid hydrolysis, alkali treatment, and microbial and enzymatic transformation, for obtaining C-K have been carried out due to the absence of C-K in ginseng \[[@pone.0191018.ref021]\]. Chemical production methods such as acid and alkali treatments induce environmental pollution, while heating method result in low selectivity and yield. In contrast, enzymatic or microbial transformation of C-K from glycosylated PPD-type ginsenosides in ginseng produces no environmental pollution with highly selective hydrolysis.

β-Glycosidase from *Sulfolobus solfataricus* has been an efficient C-K-producing enzyme using glycosylated PPD-type ginsenosides as substrates because of its broad hydrolysis activity, including β-[d]{.smallcaps}-glucopyranosidase, β-[d]{.smallcaps}-galactopyranosidase, β-[d]{.smallcaps}-xylopyranosidase, and α-[l]{.smallcaps}-arabinopyranosidase activity \[[@pone.0191018.ref022]\]. However, this enzyme showed a critical problem that the hydrolysis on PPD-type ginsenosides with α-[l]{.smallcaps}-arabinofuranoside was low or absent, and most of these ginsenosides were not hydrolyzed into C-K and accumulated. Among the PPD-type ginsnosides, Rc, compound Mc~1~ (C-Mc~1~) and compound Mc (C-Mc) contain α-[l]{.smallcaps}-arabinofuranoside in the dammarane skeleton. When the outer β-[d]{.smallcaps}-glucopyranoside at C-3 position in Rc is hydrolyzed, it is converted to C-Mc~1~, which is converted to C-Mc by cleaving the inner β-[d]{.smallcaps}-glucopyranoside in C-Mc~1~. β-Glycosidase from *S*. *solfataricus* does not hydrolyze α-[l]{.smallcaps}-arabinofuranoside linked to Rc, but slightly hydrolyzed α-[l]{.smallcaps}-arabinofuranoside linked to C-Mc because of its low α-[l]{.smallcaps}-arabinofuranosidase activity. As a result, most of it is accumulated. However, α-[l]{.smallcaps}-arabinofuranosidases from diverse microorganisms show no activity for other glycosides, and it is not suitable for C-K production \[[@pone.0191018.ref008]\]. Therefore, effective production of C-K from PPD-type ginsenosides requires a variant β-glucosidase with high hydrolysis activity for α-[l]{.smallcaps}-arabinofuranoside linked to ginsenosides.

In this study, C-Mc docking in homology model, sequence alignment with β-glycosidase from *Pyrococcus furiosus* containing α-[l]{.smallcaps}-arabinofuranosidase activity, and site-directed mutagenesis, time-course reactions were performed. As a result, a L213A variant with increased α-[l]{.smallcaps}-arabinofuranosidase activity was obtained. The activity of the L213A variant enzyme for α-[l]{.smallcaps}-arabinofuranoside linked to ginsenosides Rc, C-Mc~1~, and C-Mc was determined and compared to that of the wild-type enzyme. The conversion of ginsenoside Rc to C-K was significantly improved by using the L213A variant enzyme with increased *α*-[l]{.smallcaps}-arabinofuranosidase activity.

Materials and methods {#sec002}
=====================

Materials {#sec003}
---------

Ginsenoside standards purchased from Ambo Institute (Seoul, Korea) and BTGin (Daejeon, Korea) were Rb~1~, Rc, F~2~, compound O (C-O), compound Y (C-Y), C-Mc, C-Mc~1~, C-K, Rb~2~, and Rd. Digoxin was purchased from Sigma (St. Louis. MO, USA) and was added to ginsenoside reaction solution as an internal standard for exact determination of ginsenosides in high-performance liquid chromatography (HPLC).

Gene cloning and site-directed mutagenesis {#sec004}
------------------------------------------

β*-*Glycosidase gene of *S*. *solfataricus* DSM 1617 (DSMZ, Braunschweig, Germany) was cloned as previously described \[[@pone.0191018.ref023]\]. Site-directed mutagenesis was performed using a Muta-Direct Site Directed Mutagenesis kit (Intron, Seougnam, Korea), and it were made by polymerase chain reaction (PCR) using synthetic oligonucleotide primers. Primers used to replace the amino acid Leu213 with Ala213 are listed below: forward (`5'-CATTCCACATTTAGTCTAGCTATTTTTGCTCCCATTTTTTGTGCATTATC GTGAAA-3'`); reverse (`5'-TTTCACGATAATGCACAAAAAATGGGAGCAAAAATAGCTAGACTAAA TGTGGAATG-3'`). The sequence of mutated PCR product was confirmed by comparing with the DNA sequence of the β-glycosidase of *S*. *solfataricus* in the pET-24 vector. The PCR product was treated with Mutazyme enzyme for the digestion of the original DNA template. After enzyme treatment, the mutant gene was transformed into competent cells of *Escherichia coli*.

Enzyme expression {#sec005}
-----------------

*E*. *coli* expressing β-glycosidase from *S*. *solfataricus* was cultivated at 37°C with shaking at 200 rpm in a 2-L Erlenmeyer flask containing 450 mL of Luria-Bertani (LB) medium supplemented with 20 μg/mL of kanamycin. In order to induce enzyme expression, 0.1 mM of isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG) as a final concentration was added at 0.8 optical density at 600 nm of the culture broth. After induction, the culture temperature and agitation were reduced 16°C and 150 rpm, respectively, and cells were further incubated for 16 h.

Enzyme preparation {#sec006}
------------------

Recombinant *E*. *coli* expressing wild-type or L213A variant enzyme was harvested and resuspended in 50 mM citrate/phosphate buffer at pH 5.5 or pH 4.5, respectively. The obtained cells were lysed using a sonicator (Sonic Dismembrator Model 100; Fisher Scientific, Pittsburgh, PA, USA) on ice for 20 min. Protein was acquired from the supernatant after centrifugation at 13,000×*g* for 10 min at 4°C, and it was heated at 70°C for 10 min to denature unwanted proteins derived from *E*. *coli* and to purify the thermophilic target protein. The suspension of heat-treated protein was centrifuged at 13,000×*g* for 10 min in order to remove aggregated proteins. The supernatant obtained was filtered using a 0.45 μm-sterile syringe filter, and the filtrate was used as the purified enzyme in subsequent experiments.

Arabinofuranosidase activity {#sec007}
----------------------------

Reactions were conducted at 80°C in 50 mM citrate/phosphate buffer (pH 5.5) containing 0.4 mg/mL ginsenoside Rc or C-Mc, and 0.15 mg/mL wild-type or variant enzyme. α-[l]{.smallcaps}-Arabinofuranosidase activities of the wild-type and variant enzymes were determined on the produced concentrations of ginsenoside Rd or C-K.

Substrate specificity {#sec008}
---------------------

The substrate specificities of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* were determined by measuring the specific activities for ginsenosides Rb~1~, Rb~2~, Rd, F~2~, C-O, C-Y, C-Mc~1~, and C-Mc. The specific activity of the variant enzyme for ginsenoside Rc was not determined because it converted Rc to not only C-Mc~1~ but also Rd. The reactions of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* were carried out at 95°C in 50 mM citrate/phosphate buffer at pH 5.5 and pH 4.5, respectively, and 4% (v/v) dimethyl sulfoxide (DMSO) by varying the enzyme concentration from 0.01 to 0.5 mg/mL and the time from 5 to 30 min. The specific activity was defined as the decreased amount of the substrate ginsenoside (nmol) per min per mg of protein.

Ligand docking {#sec009}
--------------

β-Glycosidase from *S*. *solfataricus* was modeled using the Build Homology Models module in Discovery Studio 4.0 (Accerlys, San Diego, CA, USA) based on the determined structure of β-glycosidase from *S*. *solfataricus* (Protein Data Bank \[PDB\] entry, 2CEQ) as a template. The substrate C-Mc was docked into the active-site pocket in the models of *S*. *solfataricus* β-glycosidase using C-DOCKER, because C-Mc has a similar structure to Rc at C-20 position. The active site defined as a sphere of radius 10 Å around the substrate-binding pocket. The receptor-ligand (enzyme-substrate) docking models giving the lowest interaction energy were chosen for subsequent rounds of docking. Changes in the binding energy between receptor and ligand (*∆E*~Binding~) were defined as *E*~Complex~ − *E*~Ligand~ − *E*~Receptor~.

Production of C-K from ginsenoside Rc {#sec010}
-------------------------------------

The reactions of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* for C-K production using ginsenoside Rc as a substrate were performed in 50 mM citrate/phosphate buffer at pH 5.5 and pH 4.5, respectively, containing 4 mM ginsenoside Rc and 12 mg/mL enzyme. The temperature in these reactions was reduced to 85°C because of the thermostability of this enzyme. The half-life at this temperature was 30 h, indicating that the enzyme is stable during the reactions. The reaction mixtures were sampled, and ginsenoside concentrations were determined using HPLC.

Analytical methods {#sec011}
------------------

Digoxin as an internal standard and *n*-butanol with an equal volume were added to the reaction solution. The solvent in the mixed solution was evaporated, and methanol was added to the evaporated sample. The concentrations of ginsenosides were determined using an HPLC system (Agilent 1100, Agilent, Santa Clara, CA, USA) at a wavelength of 203 nm with a C18 column (YMC, Kyoto, Japan). The column was eluted at 37°C with a linear gradient of acetonitrile/water ranging from 30:70 to 90:10 (v/v) for 95 min at a flow rate of 1 mL/min. Ginsenoside type was identified using the same retention time as that for the ginsenoside standards.

Results and discussion {#sec012}
======================

Selection of a C-K-producing enzyme from ginsenoside Rc {#sec013}
-------------------------------------------------------

The enzymatic hydrolysis of ginsenoside Rc to PPD-type minor ginsenosides by various microbial enzymes, including α-[l]{.smallcaps}-arabinofuranosidases, β-glucosidases, and β-glycosidases is present in [Table 1](#pone.0191018.t001){ref-type="table"}. α-[l]{.smallcaps}-Arabinofuranosidases from various microorganisms convert Rc to Rd by hydrolyzing only α-[l]{.smallcaps}-arabinofuranoside, while the Rd is not further hydrolyzed by these enzymes. β-Glucosidases and β-glycosidases from various microorganisms transform ginsenoside Rc to C-Mc~1~, C-Mc, aglycone protopanaxadiol (APPD), and C-K. Among these enzymes, only two enzymes could convert ginsenoside Rc to C-K. β-Glycosidase from *P*. *furiosus* produced C-K as an intermediate, which was completely hydrolyzed to APPD \[[@pone.0191018.ref024]\], and β-glycosidase from *S*. *solfataricus* produced C-K as an end product, which hydrolyzes two glucose in C-3, but does not hydrolyze arabinose in C-20 at Rc. Thus, β-glycosidase from *P*. *furiosus* and *S*. *solfataricus* were selected as a comparison target enzyme and a source enzyme for the increased biotransformation of ginsenoside Rc to C-K, respectively.

10.1371/journal.pone.0191018.t001

###### Enzymatic hydrolysis of ginsenoside Rc to PPD-type ginsenosides.

![](pone.0191018.t001){#pone.0191018.t001g}

  Microorganism                            Enzyme                                  Intermediate product   Product   Reference
  ---------------------------------------- --------------------------------------- ---------------------- --------- ----------------------------
  *Thermotoga thermarum*                   α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref030]\]
  *Leuconostoc sp*.                        α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref031]\]
  *Caldicellulosiruptor saccharolyticus*   α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref032]\]
  *Rhodanobacter ginsenosidimutans*        α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref028]\]
  *Bifidobacterium longum*                 α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref033]\]
  *Bifidobacterium breve*                  α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref034]\]
  *Panax ginseng*                          α-[l]{.smallcaps}-Arabinofuranosidase   NR                     Rd        \[[@pone.0191018.ref035]\]
  *Thermus caldophilus*                    β-Glycosidase                           NR                     Rd        \[[@pone.0191018.ref036]\]
  *Sphingopyxis alaskensis*                β-Glucosidase                           NR                     C-Mc~1~   \[[@pone.0191018.ref037]\]
  *Arthrobacter chlorophenolicus*          β-Glucosidase                           NR                     C-Mc~1~   \[[@pone.0191018.ref038]\]
  *Sphingomonas* sp. 2F2                   β-Glucosidase                           NR                     C-Mc~1~   \[[@pone.0191018.ref039]\]
  *Penicillium aculeatum*                  β-Glucosidase                           C-Mc~1~                C-Mc      \[[@pone.0191018.ref040]\]
  *Dictyoglomus turgidum*                  β-Glucosidase                           ND                     C-Mc      \[[@pone.0191018.ref041]\]
  *Sulfolobus acidocaldarius*              β-Glycosidase                           ND                     C-Mc      \[[@pone.0191018.ref042]\]
  *Pyrococcus furiosus*                    β-Glycosidase                           Rd, C-K                APPD      \[[@pone.0191018.ref024]\]
  *Sulfolobus solfataricus*                β-Glycosidase                           C-Mc                   C-K       \[[@pone.0191018.ref029]\]

NR, not reported; ND, not detected

β-Glycosidase from *S*. *solfataricus* is an effective C-K producer because the enzyme can hydrolyze β-[d]{.smallcaps}-glucopyranose linked to C-3, outer β-[d]{.smallcaps}-glucopyranose, α-[l]{.smallcaps}-arabinopyranose, α-[l]{.smallcaps}-arabinofuranose, and β-[d]{.smallcaps}-xylopyranose linked to C-20 of the dammarane skeleton in PPD-type ginsenosides but does not hydrolyze inner β-[d]{.smallcaps}-glucopyranose linked to C-20 \[[@pone.0191018.ref025]--[@pone.0191018.ref028]\]. β-Glycosidase from *S*. *solfataricus* can hydrolyze β-[d]{.smallcaps}-glucopyranoside linked to ginsenosides such as Rc, C-Mc~1~, and C-Mc, which are converted into C-Mc1, C-Mc, and C-K, respectively. However, this enzyme showed low or no hydrolytic activity on α-[l]{.smallcaps}-arabinofuranoside linked to Rc, C-Mc~1~, and C-Mc. For the efficient biotransformation of ginsenoside Rc to C-K, a β-glycosidase variant with increased α-[l]{.smallcaps}-arabinofuranosidase activity should be achieved.

Achievement of a variant β-glycosidase from *S*. *solfataricus* with increased α-[l]{.smallcaps}-arabinofuranosidase activity {#sec014}
-----------------------------------------------------------------------------------------------------------------------------

In order to identify the residue involved in α-[l]{.smallcaps}-arabinofuranoside hydrolysis, a C-Mc docked model was constructed based on the reported crystal structure of β-glycosidase from *S*. *solfataricus*. Rc could not docked to the wild-type β-glycosidase because it has a large molecular size. The outer α-[l]{.smallcaps}-arabinofuranoside at C-20 of C-Mc is the same as that of the smaller molecular size Rc. Therefore, we used C-Mc in docking to β-glycosidase from *S*. *solfataricus*, instead of Rc. In the ligand docked model, four non-catalytic and two catalytic residues within a 4 Å of the substrate were identified. The non-catalytic residues were Leu213, Glu217, Lys219, and His342 and the catalytic residues were Glu206 and Glu387 ([Fig 1A](#pone.0191018.g001){ref-type="fig"}). Since β-glycosidase from *P*. *furiosus* showed high hydrolytic activity on α-[l]{.smallcaps}-arabinofuranoside linked to ginsenosides Rc and C-Mc \[[@pone.0191018.ref024]\], the sequence of β-glycosidase from *S*. *solfataricus* was aligned with that of β-glycosidase from *P*. *furiosus* that has α-[l]{.smallcaps}-arabinofuranosidase activity to determine candidate residues involved in α-[l]{.smallcaps}-arabinofuranosidase activity in β-glycosidase from *S*. *solfataricus* ([Fig 1B](#pone.0191018.g001){ref-type="fig"}). Glu206, and Glu387 were all conserved in the two enzymes. Therefore, Leu213, Glu217, Lys219, and His342 were selected as candidate residues.

![Construction of ligand docked pose and sequence alignment on *S*. *solfataricus* β*-*glycosidase.\
(A) Docking of C-Mc to *S*. *solfataricus* β*-*glycosidase in the homology model. The C-Mc ligand was docked to the active site of β*-*glycosidase from *S*. *solfataricus* (2CEQ), and amino acid residues within 4 Å distance of the substrate in the ligand docked model were selected. The selected non-catalytic residues, catalytic residues, and C-Mc are colored with red, blue, and green, respectively. (B) Amino acid sequence alignment of *S*. *solfataricus* β*-*glycosidase with *P*. *furiosus* β*-*glycosidase. The catalytic residues (Glu206 and Glu387) and non-catalytic residues (Leu213, Glu217, Lys219, and His342) of *S*. *solfataricus* β*-*glycosidase are colored with red and blue boxes, respectively.](pone.0191018.g001){#pone.0191018.g001}

The candidate residues were mutated as shown in [Table 2](#pone.0191018.t002){ref-type="table"}. The wild-type and Lys219, and His342 variant enzymes showed no hydrolytic activity on α-[l]{.smallcaps}-arabinofuranoside linked to Rc, while the Glu217 variant enzyme exhibited no hydrolytic activity on α-[l]{.smallcaps}-arabinofuranoside linked to C-Mc. However, the L213A, L213Q, and L213W variant enzymes hydrolyzed α-[l]{.smallcaps}-arabinofuranoside linked to both Rc and C-Mc, while the L213A variant enzyme showed higher α-[l]{.smallcaps}-arabinofuranosidase activity than those of the L213Q and L213W variant enzymes. Thus, we used the L213A variant enzyme for hydrolysis of α-[l]{.smallcaps}-arabinofuranoside linked to Rc and C-Mc. α-[l]{.smallcaps}-Arabinofuranosidase hydrolyzes α-[l]{.smallcaps}-arabinofuranoside linked to Rc to form Rd, but not β-[d]{.smallcaps}-glucopyranosides linked to Rd and the wild-type β-glycosidase from *S*. *solfataricus* cannot hydrolyzes α-[l]{.smallcaps}-arabinofuranoside linked to Rc, indicating that the enzymes do not convert Rd and Rc into C-K, respectively. In contrast, the L213A variant can convert Rd and Rc into C-K.

10.1371/journal.pone.0191018.t002

###### Produced concentrations of ginsenoside Rd and C-K from ginsenoside Rc and C-Mc, respectively, by the wild-type and variant β-glycosidases of *S*. *solfataricus*.

Numerical values in round brackets present the experimental data under optimum conditions (95°C, pH 4.5, and 4% DMSO).

![](pone.0191018.t002){#pone.0191018.t002g}

  Enzyme      Product (*μ*M)          
  ----------- ----------------------- -----------------------
  Wild-type   0                       198 ± 3.0
  L213A       63.4 ± 1.1 (75.7±0.8)   386 ± 2.0 (437 ± 3.0)
  L213Q       19.7 ± 0.4              343 ± 4.0
  L213R       0                       0
  L213W       11.9 ± 0.2              209 ± 4.0
  L213S       10.3 ± 0.1              0
  L213G       26.1 ± 0.5              0
  L213D       2.7 ± 0.1               0
  L213E       1.4± 0.1                0
  L213H       1.8 ± 0.1               0
  G217A       4.8 ± 0.1               0
  G217N       23.4 ± 0.4              0
  K219R       0                       259 ± 2.0
  H342A       0                       243.0 ± 3.0
  H342E       0                       0

ND, not detected

Substrate specificities of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* for PPD-type ginsenosides {#sec015}
----------------------------------------------------------------------------------------------------------------------------

The substrate specificities of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* were determined using the PPD-type ginsenosides C-Mc, C-Mc~1~, Rd, Rb~1~, Rb~2~, F~2~, C-O, and C-Y ([Table 3](#pone.0191018.t003){ref-type="table"}). The specific hydrolytic activities for the wild-type and L213A variant enzymes followed the order F2 \> Rb~1~ \> C-O \> C-Y \> Rb~2~ \> Rd \> C-Mc\> C-Mc~1~ and F~2~ \> Rb~1~ \> C-O \> C-Y \> Rb~2~ \> C-Mc \> Rd \> C-Mc~1~, respectively. The wild-type enzyme exhibited no α-[l]{.smallcaps}-arabinofuranosidase activity for ginsenoside Rc, but the L213A variant enzyme showed. The activity of the L213A variant enzyme for C-Mc was 2.2-fold higher than that of the wild-type enzyme, respectively, whereas that for C-Y was 1.5-fold lower, indicating increased α-[l]{.smallcaps}-arabinofuranosidase activity and decreased α-[l]{.smallcaps}-arabinopyranosidase activity, respectively. To explain the increased α-[l]{.smallcaps}-arabinofuranosidase activity of the L213A variant, we calculated the changes in binding energy (*∆E*~binding~) of the ligand-binding enzymes. The changes in the binding energy of the wild-type and L213A variant β-glycosidases docked with C-Mc were −86.5 and −177.2 kcal mol^−1^, respectively. The 2-fold lower binding energy of the variant β-glycosidase suggests that it has a higher regioselectivity and forms a more stable complex.

10.1371/journal.pone.0191018.t003

###### Substrate specificity of the wild-type and L213A variant β- glycosidase from *S*. *solfataricus* for the PPD-type ginsenosides.

![](pone.0191018.t003){#pone.0191018.t003g}

  Substrate   Product   Specific activity (nmol/min/mg)   
  ----------- --------- --------------------------------- -------------
  C-Mc        C-K       66.1 ± 0.9                        146 ± 0.5
  C-Mc~1~     C-K       12.6 ± 1.3                        56.7 ± 0.9
  Rd          C-K       211 ± 2.9                         80.2 ± 1.8
  Rb~1~       C-K       8560 ± 120                        13650 ± 290
  Rb~2~       C-K       520 ± 10                          540 ± 10
  F~2~        C-K       24100 ± 150                       33400 ± 210
  C-O         C-K       4240 ± 110                        4050 ± 20
  C-Y         C-K       1740 ± 10                         1180 ± 10

Transformation pathways of the wild-type and L213A variant β-glycosidases from *S*. *solfataricus* {#sec016}
--------------------------------------------------------------------------------------------------

The transformation pathway of ginsenoside Rb~1~, Rb~2~, Rc, or Rd to C-K by the wild-type β-glycosidase from *S*. *solfataricus* was previously reported as Rb~1~ or Rb~2~ → Rd → F~2~ → C-K, and Rc → C-Mc~1~ → C-Mc → C-K \[[@pone.0191018.ref029]\]. Ginsenoside Rc was not converted to Rd due to an absence of α-[l]{.smallcaps}-arabinofuranosidase activity of the wild-type enzyme for ginsenoside Rc. The L213A variant enzyme included the pathway of Rc → Rd → F~2~ → C-K in addition to the previous one due to its α-[l]{.smallcaps}-arabinofuranosidase activity for ginsenoside Rc ([Fig 2](#pone.0191018.g002){ref-type="fig"}). The wild-type and L213A variant enzymes converted C-O and C-Y into C-K ([Table 3](#pone.0191018.t003){ref-type="table"}). The enzymes converted Rb2 into not only Rd as a major product but also C-O as a minor product. Thus, we established another C-K-producing transformation pathway: Rb~2~ → C-O → C-Y → C-K in the wild-type and L213A variant enzymes.

![Biotransformation pathways from ginsenosides Rb~1~, Rb~2~, and Rc to C-K by the wild-type and L213A variant β-glycosidases from *S*. *solfataricus*.\
The black arrow indicates newly formed hydrolytic activity by the L213A variant.](pone.0191018.g002){#pone.0191018.g002}

C-K production from ginsenoside Rc and C-Mc by wild-type and L213A variant β-glycosidases from *S*. *solfataricus* {#sec017}
------------------------------------------------------------------------------------------------------------------

The time-course reactions of Rc to C-K by the wild-type and L213A variant enzymes were quantitatively analyzed by the HPLC system. The wild-type and L213A variant β-glycosidases from *S*. *solfataricus* converted 4 mM ginsenoside Rc to 2.5 mM C-K via C-Mc and 3.8 mM C-K via Rd and C-Mc, respectively, in 10 h. The molar conversions of these reactions were 62% and 97%, respectively ([Fig 3](#pone.0191018.g003){ref-type="fig"} and [Fig 4](#pone.0191018.g004){ref-type="fig"}). The amount of C-K produced from Rc by the variant enzyme was 1.5-fold higher than that by the wild-type enzyme. The wild-type and variant enzymes converted 4 mM C-Mc to 1.9 mM and 3.8 mM C-K, respectively, in 14 h. The molar conversions were 47% and 97%, respectively ([Fig 5](#pone.0191018.g005){ref-type="fig"} and [Fig 6](#pone.0191018.g006){ref-type="fig"}). The amount of C-K produced from Rc by the variant enzyme was 2.0-fold higher than that by the wild-type enzyme.

![**C-K production from ginsenoside Rc via C-Mc with Rd and C-Mc as intermediates by (A) the wild-type and (B) L213A variant *β-*glycosidases from *S*. *solfataricus*, respectively.** Ginsenoside Rc (filled circle), Rd (open circle), C-Mc (filled triangle), and C-K (filled square).](pone.0191018.g003){#pone.0191018.g003}

![HPLC profiles of the reaction solutions obtained after 4 h and 10 h for the production of C-K from ginsenoside Rc by (A) the wild-type and (B) L213A variant β*-*glycosidases from *S*. *solfataricus*.](pone.0191018.g004){#pone.0191018.g004}

![**C-K production from ginsenoside Mc by (A) the wild-type and (B) L213A variant *β-*glycosidases from *S*. *solfataricus*.** Ginsenoside C-Mc (filled triangle), and C-K (filled square).](pone.0191018.g005){#pone.0191018.g005}

![HPLC profiles of the reaction solutions obtained after 14 h for the production of C-K from ginsenoside Mc by (A) the wild-type and (B) L213A variant enzymes from *S*. *solfataricus*.](pone.0191018.g006){#pone.0191018.g006}

Conclusions {#sec018}
===========

β-glycosidase from *S*. *solfataricus* is the most efficient producer of C-K from PPD-type ginsenosides. However, this enzyme has a critical problem in that low or no hydrolytic activity is seen on α-[l]{.smallcaps}-arabinofuranoside linked to ginsenosides. To solve this problem, an L213A variant with increased α-[l]{.smallcaps}-arabinofuranosidase activity was obtained through protein engineering based on a ligand docked homology model and sequence alignment. The variant enzyme converted ginsenoside Rc and C-Mc to C-K with both molar conversions of 97%, which was 35% and 50% higher than the wild-type enzyme, respectively. Therefore, protein engineering is a useful tool for enhancing the hydrolytic activity of specific glycosides linked to ginsenosides.
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